The Academic Trap in Action: How Pathway Bio Stopped Explaining the Science and Started Explaining the Win
Pathway Bio's site undersold the intensity of its oncology platform. This case study covers the patient-first positioning line that replaced the mechanism, the multi-page, motion-led website built to land close to the standard set by the best biotech sites on a startup budget, and the pitch deck to support their next funding round.
The Academic Trap in Action: Pathway Bio
This is the first in an occasional series walking through delivered Marshall Studio client work through the Academic Trap lens: what the problem was, what changed, and what it did for the company.
Pathway Bio is a precision medicine and oncology company, and Bobby Kaura is its Founder and CEO. Over a 12-week engagement I delivered a clinical brand identity and a multi-page Webflow website for the company. I also helped with their pitch deck, to support their next funding round.
Before: The How Was Crowding Out the Why It Matters
The science was never the issue. The issue was that the site and brand didn't say much about the actual problem Pathway Bio solves. The previous messaging didn't reflect the scientific intensity of the platform, and it undersold what the benefit meant to the clinicians and patients on the other side of it. The company needed something that would inspire confidence in clinicians and institutional investors.
This is the Academic Trap in one of its clearest forms. It isn't that the site was wrong or badly built. It's that a company doing something significant for cancer patients was explaining itself in a register that left the significance out, with the how present, or absent, and no clear why attached to it.
After: A Plain, Patient-First Line Leading Everything
The new positioning leads with a line that does the opposite: "Cancer is as unique as the individual themselves. We will treat it as such. Whenever possible, treatment should be informed by the patient's individual biology."
That's outcome-first, patient-first language replacing whatever came before. It doesn't ask the reader to understand a mechanism before they understand what the company is trying to do for them. It states the commitment plainly, and the science sits underneath it as the reason the commitment is credible, not as the thing standing between the reader and the point.
The Brief Behind the Brief: Match the Best on a Real Budget
A better line was only half the job. The other half was how the company would look and feel the moment someone landed on the site. The best science websites are cinematic, confident and clearly built by people who expect to be taken seriously, and Colossal Biosciences is the benchmark I had in mind. My aim for Pathway Bio was to get on par with that standard, or as close as I could, within a budget a growing company can actually justify.
That meant building the site to look as high end as I physically could, with custom animation and video throughout, while keeping the structure simple enough for a visitor to follow in seconds.
A Multi-Page Site That Tells One Story
This isn't a single landing page. It's a multi-page site, with a homepage plus Technology, Team, News and Contact pages, and every page sounds like the same company.
The story runs in order. The site opens on the patient-first line over cellular imagery, then moves through the problem, the solution and how it works. The problem is stated in three words, "Unproven. Uncertain. Unacceptable.", and each section carries a small label and marker so the visitor always knows where they are. Nobody has to decode a pipeline diagram to find out why the company exists.
Method becomes steps. Instead of a wall of technical description, the process is broken into numbered steps, each with a plain headline, a custom icon and a "Pathway Advantage" line on what it means for the clinician. A ticker runs the whole pipeline in four words: data, prediction, validation, therapy.
Proof sits where it can't be missed. The problem statistics carry their sources, and the reach of the platform is shown as large numbers instead of being buried in a paragraph.
The people and the enquiry are handled with care. The team appears in a consistent branded portrait treatment, and the contact page asks what kind of enquiry it is, whether a question, a partnership or a press request, before the message is written.
Motion carries the feel. A branded loader, cellular visuals, video and custom animation make the site feel as advanced as the platform it describes, and the footer closes on the company's own three words: tested, tailored, guided.
The Pitch Deck: One Story, Built for the Next Round
The Academic Trap doesn't only live on websites. It lives in decks too, and investors check the two side by side, so they notice when they disagree. I also helped Pathway Bio with their pitch deck, to support their next funding round. The same principle applies: lead with what changes for the patient, then let the science back it up, and keep the deck and the site telling one consistent story.
The Result
Looking at the finished site, I'm confident it landed on par with the standard I set, or very close to it, at a budget a startup can stand behind. It now looks as ambitious as the science it describes, and it opens with one human line instead of a mechanism. You can see it live at pwbio.ai, or read the Pathway Bio case study.
In the Founder's Words
The feedback I got from Bobby came down to this: I understood both the science and the long-term vision, the finished site reads as clear, professional and credible, timelines were respected, his feedback was heard, and the process felt collaborative. The brand now feels aligned with what the company actually stands for. Bobby also recorded a short video, which you can watch here.
The Transferable Lesson
Precision medicine and oncology are among the hardest categories to de-jargon, because the science is genuinely complex and the instinct to explain it carefully is a good instinct in the wrong place. The fix here wasn't to simplify the science or hide it. It was to reorder what came first: the human commitment, then the biology that backs it up.
Any founder in a technically dense field can ask the same question of their own site. If a patient, a clinician, or an investor read only the first line, would they understand what the company is trying to do for them, or would they need to already understand the mechanism first?
This project added a second question: does the site look as serious as the science? The two work together. The right line on a site that looks as ambitious as the company is what gets a reader past the first five seconds, and the bar for that is now within reach of a startup budget, which I wrote about in Your Science Is High-End. There's No Excuse for a Website That Isn't.
Ready to tell your story
Let's build a narrative that moves people and drives results